#dapsone

The global market for Dermatitis Herpetiformis treatments was estimated at approximately USD 1.2 billion in 2024 and is expected to reach around USD 2.5 billion by 2033, growing at a robust ~9.1% CAGR. Growth is driven by rising diagnosis rates, greater awareness of gluten-related autoimmune conditions, and continued reliance on effective symptomatic relief medications like dapsone. While gluten-free diets remain the cornerstone of long-term care, immediate symptom management through drugs is essential—and demand continues to rise.

North America leads the market, supported by advanced healthcare infrastructure and high diagnosis accuracy, while Asia-Pacific is projected to grow fastest thanks to improving access to dermatological care and dietary therapies. Dapsone remains the primary therapeutic agent, with oral and topical corticosteroids also used. Distribution channels are dominated by retail pharmacies, followed by online and hospital pharmacies.

Top Players in the Market: 🏥 GlaxoSmithKline Pharmaceuticals 🏭 Pfizer Inc. 🧪 Allergan 🏢 Valeant Canada LP 🔬 Nostrum Laboratories Inc.

The U.S. Food and Drug Administration (FDA) approved to market Aczone (dapsone) Gel, 5 per cent for acne vulgaris topical treatment. But patients who have the enzyme deficiency, G6PD (Glucose 6-phosphate dehydrogenase), will need to be monitored with regular blood counts to detect if they are predisposed to one type of anemia (hemolytic anemia).

Aczone, a trademark of QLT USA Inc., is an aqueous…

This report studies sales (consumption) of Dapsone in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering

TCI

HBCChem